Regulatory8 July 2026· 9 min read
How NICE Evaluates Orphan Drugs Under the HST Programme
For most licensed medicines that reach the NHS in England, the route to routine clinical use runs through the NICE single technology appraisal (STA) process: a structured assessment of clinical and cost-effectiveness that applies a cost-per-quality-adjusted-life-year (QALY)…
By Dr. Eleanor Vance, Regulatory Affairs Editor